Filing Overview
The provided Form 10-Q identifies the registrant as Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarter ended March 31, 2014, with comparative information for the three months ended March 31, 2013. The company develops human neuronal stem-cell therapies and small-molecule compounds, with programs including NSI-566 and NSI-189. Its securities filings state that all principal product candidates remained in preclinical or clinical development and had generated no commercial product revenue.
Financial Results and Position
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue | $4,167 | $102,500 | Down 96% |
| Research and development expense | $1.57 million | $1.75 million | Down 10% |
| General and administrative expense | $3.52 million | $1.20 million | Up 194% |
| Total operating expenses | $5.18 million | $2.99 million | Up 73% |
| Operating loss | $(5.18) million | $(2.89) million | Loss widened |
| Net loss | $(5.92) million | $(3.59) million | Loss widened |
| Basic and diluted loss per share | $(0.07) | $(0.05) | More negative |
| Cash used in operating activities | $(2.71) million | $(2.51) million | Use increased |
Revenue consisted solely of intellectual-property licensing fees; the company reported no revenue from product sales. Other expense was $742,156, including $432,741 of interest expense and a $334,133 loss from the change in fair value of warrant-related derivative instruments.
At March 31, 2014, cash and cash equivalents were $18.34 million, short-term investments were $15.00 million, total assets were $35.92 million, and stockholders’ equity was $26.90 million. Current liabilities were $4.67 million and total liabilities were $9.03 million. The company reported working capital of approximately $29.44 million.
The company’s debt consisted primarily of a secured term loan. Debt was approximately $7.3 million in aggregate principal amount, with a stated variable interest rate based on prime subject to an 11% floor, maturity in June 2016, and monthly principal and interest payments of approximately $300,000. Substantially all assets, including intellectual property, secured the loan.
Material Changes Versus Prior Period
- Revenue declined by approximately $98,000 because Q1 2013 included an upfront licensing fee, while Q1 2014 reflected ongoing fees only.
- Research and development expense decreased by approximately $177,000, primarily because certain projects did not continue into Q1 2014 and some 2014 studies were subsidized by third parties.
- General and administrative expense increased by approximately $2.32 million. The principal driver was approximately $2.02 million of stock-based compensation related to extending a consultant’s warrant term after achievement of performance milestones; legal and professional fees also increased by approximately $227,000.
- Share-based compensation increased to $2.44 million from $477,000, with approximately $2.21 million recorded in general and administrative expense.
- Cash from financing activities increased to $19.43 million from $7.83 million, primarily due to a January 2014 registered direct offering that generated approximately $18.68 million of net proceeds, partially offset by $705,000 of debt payments.
- The company purchased $15.00 million of short-term investments, materially increasing investing cash use while preserving liquidity in investment form.
- Warrants underlying the $1.42 million derivative liability at December 31, 2013 were exercised in Q1 2014, leaving no recurring fair-value derivative liability at March 31, 2014.
- Shares outstanding increased to 86.69 million at March 31, 2014 from 77.89 million at December 31, 2013; additional dilution remained possible from approximately 44.5 million reserved shares and outstanding options, warrants, and other awards.
Outlook, Commentary, Risks, and Unusual Items
- Management expected available cash and anticipated income to fund current activities at least through March 31, 2015, but stated that long-term cash was inadequate to fund the full range of required development and clinical testing.
- Management expected continuing operating losses and negative cash flows and stated that the company would need substantial additional capital. Approximately $14.0 million remained available under its $50 million shelf registration statement.
- Clinical expectations included completion of NSI-566 ALS Phase II dosing near the end of Q2 2014, commencement of a chronic spinal cord injury Phase I trial during Q2 2014, completion of the initial ischemic-stroke trial phase in Q1 2015, and filing an NSI-189 Phase II IND in Q3 2014 with a trial expected to begin in late 2014 or early 2015.
- The company planned to increase internal GMP manufacturing capacity following its headquarters relocation, with anticipated readiness for clinical-trial stem-cell manufacturing by Q2 2015.
- Key risks include clinical-trial failure or delay, uncertain FDA and foreign regulatory approval, reliance on third-party manufacturers and clinical research organizations, intellectual-property disputes, need for additional financing, debt covenant and repayment requirements, potential dilution, and lack of commercial revenue.
- Neuralstem was involved in longstanding patent litigation with StemCells, Inc. A standing hearing was scheduled for May 19, 2014; the outcome could resolve the matter or permit the litigation to proceed to expert discovery. Management believed ordinary litigation would not materially affect the company, but the ultimate outcome was uncertain.
- The filing reported no material subsequent transactions through the financial-statement issuance date and stated that disclosure controls and procedures were effective with no material change in internal control over financial reporting.
Investor Verification Items
- Confirm the registrant identity: the supplied filing is for Neuralstem, Inc., despite the request metadata naming Palisade Bio, Inc.
- Verify current cash runway after accounting for operating cash burn, approximately $300,000 monthly debt service, clinical-trial spending, and planned manufacturing investment.
- Review the terms, covenants, collateral, interest rate, and repayment schedule of the secured debt.
- Assess potential dilution from the 2014 equity offering, outstanding warrants and options, and approximately 44.5 million reserved shares.
- Track the outcomes and timing of the NSI-566 and NSI-189 clinical and regulatory milestones.
- Review the StemCells patent litigation and any effect on commercialization rights, costs, or intellectual-property protection.
- Reconcile the unusually large stock-based compensation charge and the related consultant warrant-term extension.